GlassScriptPhysician profile
John Valentino
NPI 1891444931
$4,200.55
in general payments reported to CMS, 2019-2025
14 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,940 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007 · Consulting Fee: $125 · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.02 |
| Consulting Fee | $124.53 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $767.06 | 2024-2025 | |
| Abbvie INC. | $743.55 | 2024-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $632.74 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $312.08 | 2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $278.42 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Janssen Scientific Affairs, LLC | $263.09 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $232.80 | 2025 | |
| Pfizer INC. | $169.14 | 2024-2025 | |
| Incyte Corporation | $164.34 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $145.09 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $135.44 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $133.33 | 2025 | |
| Biofrontera INC. | $124.53 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $98.94 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Valentino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.